These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37589730)

  • 21. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
    Storebø OJ; Pedersen N; Ramstad E; Kielsholm ML; Nielsen SS; Krogh HB; Moreira-Maia CR; Magnusson FL; Holmskov M; Gerner T; Skoog M; Rosendal S; Groth C; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Håkonsen SJ; Aagaard L; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012069. PubMed ID: 29744873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylphenidate treatment of attention-deficit/hyperactivity disorder secondary to traumatic brain injury: a critical appraisal of treatment studies.
    Jin C; Schachar R
    CNS Spectr; 2004 Mar; 9(3):217-26. PubMed ID: 14999162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
    Moungnoi P; Maipang P
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356
    [No Abstract]   [Full Text] [Related]  

  • 25. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS).
    McCarthy S; Neubert A; Man KKC; Banaschewski T; Buitelaar J; Carucci S; Coghill D; Danckaerts M; Falissard B; Garas P; Häge A; Hollis C; Inglis S; Kovshoff H; Liddle E; Mechler K; Nagy P; Rosenthal E; Schlack R; Sonuga-Barke E; Zuddas A; Wong ICK
    BMC Psychiatry; 2018 Oct; 18(1):327. PubMed ID: 30305167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis: Dose-Dependent Effects of Methylphenidate on Neurocognitive Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
    Vertessen K; Luman M; Staff A; Bet P; de Vries R; Twisk J; Oosterlaan J
    J Am Acad Child Adolesc Psychiatry; 2022 May; 61(5):626-646. PubMed ID: 34534624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):342-349. PubMed ID: 34081560
    [No Abstract]   [Full Text] [Related]  

  • 30. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
    Eaton C; Yong K; Walter V; Mbizvo GK; Rhodes S; Chin RF
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD013136. PubMed ID: 35844168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Influence of methylphenidate on growth of school age children with attention deficit hyperactivity disorder].
    Zhang HY; Du ML; Zhuang SQ; Liu MN
    Zhonghua Er Ke Za Zhi; 2005 Oct; 43(10):723-7. PubMed ID: 16255846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response.
    Grebla R; Setyawan J; Park C; Richards KM; Nwokeji ED; Pawaskar M; Haim Erder M; Lawson KA
    J Med Econ; 2019 Aug; 22(8):788-797. PubMed ID: 30983465
    [No Abstract]   [Full Text] [Related]  

  • 34. A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study.
    Hegvik TA; Jacobsen KK; Fredriksen M; Zayats T; Haavik J
    J Neural Transm (Vienna); 2016 Aug; 123(8):859-65. PubMed ID: 27091191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate.
    Hautmann C; Rothenberger A; Döpfner M
    BMC Psychiatry; 2013 Sep; 13():219. PubMed ID: 24004962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2013; 36(5):141-5. PubMed ID: 24045603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis.
    Farhat LC; Flores JM; Behling E; Avila-Quintero VJ; Lombroso A; Cortese S; Polanczyk GV; Bloch MH
    Mol Psychiatry; 2022 Mar; 27(3):1562-1572. PubMed ID: 35027679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder.
    Chen VC; Yang YH; Yu Kuo T; Lu ML; Tseng WT; Hou TY; Yeh JY; Lee CT; Chen YL; Lee MJ; Dewey ME; Gossop M
    Epidemiol Psychiatr Sci; 2020 Jul; 29():e146. PubMed ID: 32686635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychostimulants: Influence on Body Mass Index and Height in a Pediatric Population with Attention-Deficit/Hyperactivity Disorder?
    Lentferink YE; van de Garde EMW; Knibbe CAJ; van der Vorst MMJ
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):530-536. PubMed ID: 29768018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.